Hepatocellular Carcinoma

Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date

Profile of Tivantinib and its Potential in the Treatment of Hepatocellular Carcinoma: the evidence to date

[Journal of Hepatocellular Carcinoma] This research examines tivantinib and its therapeutic profile in the management of hepatocellular carcinoma.

Hepatocellular Carcinoma: A Review

Hepatocellular Carcinoma: A Review

[Journal of Hepatocellular Carcinoma] This research examines the screening modalities, diagnosis, staging, and treatment of hepatocellular carcinoma (HCC), the most common primary liver malignancy.

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

[Journal of Hepatocellular Carcinoma] This review examines the multikinase inhibitors sorafenib and regorafenib, inhibitors of the MET pathway, and immunotherapeutics for the treatment of advanced hepatocellular carcinoma.

Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score

Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score

By

In patients with advanced HCC and a baseline αFP level of 400 ng/mL or more, a survival benefit with second-line ramucirumab therapy was observed for those with Child-Pugh scores of 5 and 6.

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

Second-Line Regorafenib Improves Overall Survival in Refractory Liver Cancer

By

The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.

Adding Doxorubicin to Sorafenib Does Not Improve Overall Survival in Hepatocellular Carcinoma

Adding Doxorubicin to Sorafenib Does Not Improve Overall Survival in Hepatocellular Carcinoma

By

In patients with advanced hepatocellular carcinoma (HCC), adding doxorubicin to sorafenib did not improve overall survival or progression-free survival and resulted in higher toxicity compared to sorafenib alone, results from a phase 3 study presented at the ASCO 2016 Annual Meeting have shown.

Metabolic Disorder Largest Risk Factor of Hepatocellular Carcinoma

Metabolic Disorder Largest Risk Factor of Hepatocellular Carcinoma

By

Metabolic disorders contribute more to the incidence of hepatocellular carcinoma (HCC) incidence than any other risk factor.

Adding Mapatumumab to Sorafenib Not Effective for Advanced HCC

Adding Mapatumumab to Sorafenib Not Effective for Advanced HCC

By

The addition of mapatumumab to sorafenib did not improve time to progression, progression-free survival, overall survival, or objective response.

Tenofovir may reduce risk of liver cancer in patients with HBV infection

Tenofovir may reduce risk of liver cancer in patients with HBV infection

Long-term therapy with tenofovir was associated with a decreased incidence of HCC among patients with chronic HBV infection without cirrhosis.

Hepatitis virus variations responsible for variations in liver cancer

By

Significant clinical variations have been identified among patients with hepatocellular carcinoma (HCC).

Emerging role of Toll-like receptor 4 in hepatocellular carcinoma

Emerging role of Toll-like receptor 4 in hepatocellular carcinoma

[Journal of Hepatocellular Carcinoma] This article explores the involvement of the TLR pathway in the initiation, progression, and metastasis of hepatocellular carcinoma (HCC).

Chemoprotective effects of coffee

Chemoprotective effects of coffee

By

Diet and nutrition are significant factors in preventing hepatic diseases progressing to hepatocellular carcinoma, and coffee is high on the list of good foods.

Oncogene driving liver cancer identified as UHRF1

By

By combining a zebrafish model of liver cancer with data from human tumors, researchers hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma.

AACR: Diabetes Linked to HCC Risk Across Ethnic Groups

AACR: Diabetes Linked to HCC Risk Across Ethnic Groups

Highest risk seen for Latinos; estimated 26 percent of HCC cases in Latinos due to diabetes

Can radiation therapy help  resolve the  liver cancer 'paradox'?

Can radiation therapy help resolve the liver cancer 'paradox'?

By

Few patients with HCC are candidates for curative treatment at diagnosis. However, a new study demonstrated that stereotactic body radiotherapy...

Treating hepatocellular carcinoma with transarterial chemoembolization and selective internal radiotherapy

By

New light was shed on the use of TACE and SIRT in the treatment of hepatocellular carcinoma (HCC) by data from clinical trials presented at the International Liver Congress 2013 in Amsterdam, the Netherlands.

Novel tests improve diagnosis of two types of liver cancer

By

New data from two clinical trials presented at the International Liver Congress 2013 demonstrated substantial improvements in the detection of both HCC and cholangiocarcinoma using diagnostic urine tests.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs